



## **Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference**

April 11, 2023

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- [Generation Bio Co.](#) (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 22<sup>nd</sup> Annual Needham Virtual Healthcare on Tuesday, April 18<sup>th</sup> at 3:00 p.m. EST.

A live webcast of the panel will be available on the investor section of the company's website at [investors.generationbio.com](https://investors.generationbio.com). A replay will be available there for 30 days following the event.

### **About Generation Bio**

Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. This approach is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues and cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio's manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit [www.generationbio.com](https://www.generationbio.com).

### **Investors and Media Contact**

Maren Killackey  
Generation Bio  
[mkillackey@generationbio.com](mailto:mkillackey@generationbio.com)  
857-371-4638